51656-70-3

Basic information

• Product Name: Zinc, bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]-
• Synonyms: Zinc, bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]-;(2-tert-butoxy-2-oxoethyl)zinc(II) bromide;bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]-
• CAS NO: 51656-70-3
• Molecular Formula: C₆H₁₁BrO₂Zn
• Molecular Weight: 260.44434
• EINECS: -0
• Mol File: 51656-70-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Zinc, bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Zinc, bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]-(51656-70-3)
• EPA Substance Registry System: Zinc, bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]-(51656-70-3)

Safety Data

• Hazardous Substances Data: 51656-70-3(Hazardous Substances Data)

Usage

Uses

Given the provided materials, there are no specific applications listed for Zinc, bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]-. However, based on the general properties of zinc and bromine compounds, we can hypothesize potential uses in various industries:
Used in Chemical Industry:
Zinc, bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]could be used as a reagent or intermediate in the synthesis of other complex organic compounds, leveraging its unique structure and the reactivity of the bromo and dimethylethoxy groups.
Used in Pharmaceutical Industry:
Given the presence of zinc, which is an essential trace element in biological systems, Zinc, bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]- might be explored for its potential biological activity, possibly serving as a precursor to pharmaceuticals or as a component in drug delivery systems.
Used in Material Science:
Zinc, bromo[2-(1,1-dimethylethoxy)-2-oxoethyl]-'s structural features might endow it with specific physical or chemical properties that could be harnessed in the development of new materials with tailored characteristics for various applications.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 7440-66-6 zinc 
• 75-77-4 chloro-trimethyl-silane 

Downstream Products

• 14734-25-9 succinic acid (methyl)(tert-butyl)diester 
• 92975-39-8 t-butyl-2-(cyclohex-2-enyl)acetate 
• 72656-48-5 tert-butyl (R)-3-hydroxy-3-phenylpropanoate 
• 52178-62-8 (-) S-β-hydroxy β-phenyl propionate de t-butyle 
• 463304-61-2 (S)-tert-butyl 3-hydroxy-3-(2-naphthyl)-3-(1-trityl-1H-imidazol-4-yl)propanoate 
• 174579-31-8 (4-aminophenyl)acetic acid tert-butyl ester 
• 726190-90-5 C₂₅H₃₃BrClNO₆ 
• 726191-22-6 tert-butyl (3R)-3-{5-chloro-3-iodo-2-[(2-methoxyethoxy)methoxy]-phenyl}-3-{[(1R)-2-hydroxy-1-phenylethyl]amino}propanoate 

Relevant articles and documents

MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS

The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl amides. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

C(sp3)?C(sp3) Bond Formation via Electrochemical Alkoxylation and Subsequent Lewis Acid Promoted Reactions

A two-step transition metal-free methodology for the C(sp3)?C(sp3) functionalisation of saturated N-heterocyclic systems is disclosed. First, aminal derivatives are generated through the anodic oxidation of readily accessible carboxylic acids. Then, in the presence of BF3 ? OEt2, iminium ions are unmasked and rapidly alkylated by organozinc reagents under flow conditions. Secondary, tertiary and quaternary carbon centers have been successfully assembled using this methodology. Such an approach is especially relevant to drug discovery since it increases C(sp3)-functionalities rapidly within a molecular framework. As proof of concept, our methodology was applied to derivatization of peptides and an API. (Figure presented.).

DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS

A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS

A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

Catalytic Asymmetric Fluorination of Copper Carbene Complexes: Preparative Advances and a Mechanistic Rationale

The Cu-catalyzed reaction of substituted α-diazoesters with fluoride gives α-fluoroesters with ee values of up to 95 %, provided that chiral indane-derived bis(oxazoline) ligands are used that carry bulky benzyl substituents at the bridge and moderately bulky isopropyl groups on their core. The apparently homogeneous solution of CsF in C6F6/hexafluoroisopropanol (HFIP) is the best reaction medium, but CsF in the biphasic mixture CH2Cl2/HFIP also provides good results. DFT studies suggest that fluoride initially attacks the Cu- rather than the C-atom of the transient donor/acceptor carbene intermediate. This unusual step is followed by 1,2-fluoride shift; for this migratory insertion to occur, the carbene must rotate about the Cu?C bond to ensure orbital overlap. The directionality of this rotatory movement within the C2-symmetric binding site determines the sense of induction. This model is in excellent accord with the absolute configuration of the resulting product as determined by X-ray diffraction using single crystals of this a priori wax-like material grown by capillary crystallization.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

NLRP3 INHIBITORS

The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.

COMPOUND, RESIN, RESIST COMPOSITION AND PRODUCTION METHOD OF RESIST PATTERN

PROBLEM TO BE SOLVED: To provide a compound from which a resist pattern with good line edge roughness (LER) can be produced. SOLUTION: The compound is represented by formula (I). In the formula, R1 represents an alkyl group having 1 to 6 carbon atoms, H, or a halogen atom; X1 represents a connecting group such as -COO-C6H5-COO-; A1 represents a single bond or the like; A3 represents an alkanediyl group having 1 to 6 carbon atoms; W represents a divalent alicyclic hydrocarbon group having 3 to 18 carbon atoms; and R2 represents a substituted/unsubstituted hydrocarbon group having 1 to 28 carbon atoms. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPO&INPIT

CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF

Biomarkers are provided that are predictive and/or indicative of a subject's responsiveness to a cyclin-dependent kinase 2 (CDK2) inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing a disease or disorder associated with CDK2 and for monitoring treatment.

SULFONYLAMIDE COMPOUNDS AS CDK2 INHIBITORS

The present application provides sulfonyl amide compounds of formula (I), which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.